Cannabinoids may ease Alzheimer’s agitation, but drowsiness matters
Cannabinoids Treatment for Agitation in Alzheimer's Disease: A Systematic Review and Meta-Analysis With Bayesian and Sequential Trial Analyses.
AI Summary
This systematic review and meta-analysis examined whether cannabinoid-based therapies can help manage agitation and other neuropsychiatric symptoms in people with Alzheimer’s disease. Across 7 studies involving 221 participants, including 6 randomized trials, treatment was associated with lower overall neuropsychiatric symptom scores, agitation scores, and agitation/aggression scores than placebo. Bayesian analyses also supported a high probability that symptoms were reduced with treatment.
The review found no consistent evidence that these therapies improve cognitive performance as measured by the Mini-Mental State Examination. Somnolence—excessive sleepiness or drowsiness—was the main safety concern, occurring more often with cannabinoid treatment; estimates for falls and fatigue were less certain. The authors caution that the evidence is limited by small trials, differing formulations and measurement tools, short follow-up, and the concentration of statistical weight in a few studies. Larger, longer trials are needed before specific cannabinoid products can be confidently recommended for Alzheimer’s-related agitation.
💡 Key Findings
📄
Original Abstract
Related Research
Similar Studies
More Mental Health research papers you might find interesting.
Brain blood-flow reductions in acute anorexia follow a cortical hierarchy
CBD showed limited adaptive-functioning differences versus placebo in boys…
Resilience linked to depression outcomes and THC positivity
Explore More Research
Stay informed about the latest cannabis science.